Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anebulo Pharmaceuticals, Inc.

2.28
-0.0900-3.80%
Post-market: 2.280.00000.00%16:04 EST
Volume:20.44K
Turnover:48.00K
Market Cap:93.67M
PE:-9.09
High:2.39
Open:2.33
Low:2.28
Close:2.37
52wk High:3.42
52wk Low:0.8001
Shares:41.08M
Float Shares:3.40M
Volume Ratio:1.09
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2509
EPS(LYR):-0.2509
ROE:-109.69%
ROA:-71.09%
PB:8.04
PE(LYR):-9.09

Loading ...

Company Profile

Company Name:
Anebulo Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
3
Office Location:
1017 Ranch Road 620 South,Suite 107,Lakeway,Texas,United States
Zip Code:
78734
Fax:
- -
Introduction:
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Directors

Name
Position
Joseph F. Lawler
Director and Chairman of the Board
Richard Anthony Cunningham
Chief Executive Officer and Director
Areta Kupchyk
Director
Aron R. English
Director
Bimal Shah
Director
Jason M. Aryeh
Director
Kenneth Lin
Director
Nathaniel Calloway
Director

Shareholders

Name
Position
Richard Anthony Cunningham
Chief Executive Officer and Director
Daniel George
Part time Chief Financial Officer
Kenneth C. Cundy
Chief Scientific Officer